LEXYAL Regulatory Status: Market Access and Certification for Professionals

LEXYAL is a hyaluronic acid (HA) dermal filler manufactured by S. Thepharm Co., Ltd., based in South Korea. As a South Korean product, its initial regulatory pathway typically involves approval from the Korea Ministry of Food and Drug Safety (KFDA). This national certification is foundational for its domestic sale and often a prerequisite for international market entry.

Professionals considering LEXYAL for their inventory should prioritize understanding its manufacturer's compliance standards. Key aspects include adherence to Good Manufacturing Practices (GMP) and relevant ISO standards, which ensure consistent product quality and safety during production. For instance, the general category of Hyaluronic acid dermal filler catalog includes a range of products where these manufacturing standards are paramount.

The regulatory landscape for aesthetic injectables varies significantly across global markets. For a product like LEXYAL to be legally distributed and used, specific certifications are required:

• KFDA Approval: As the country of origin, KFDA approval confirms LEXYAL meets South Korean safety and efficacy standards. Its current KFDA approval status is [VERIFY: LEXYAL KFDA approval status]. This is often the first regulatory hurdle a Korean-manufactured product clears.
• CE Mark: Essential for distribution within the European Union (EU) and other regions that recognize CE certification (e.g., UK, EFTA states). A CE Mark indicates conformity with EU health, safety, and environmental protection standards. LEXYAL's current CE Mark status is [VERIFY: LEXYAL CE Mark status and specific class (e.g., Class III medical device)].
• FDA Approval: United States Food and Drug Administration (FDA) approval is typically required for sale in the US market. Achieving FDA approval is a rigorous process. LEXYAL's current FDA approval status for the US market is [VERIFY: LEXYAL FDA approval status].
• GMP/ISO Standards: S. Thepharm Co., Ltd., as a manufacturer of medical devices, is expected to operate under ISO 13485 (Medical devices - Quality management systems) and maintain Good Manufacturing Practices (GMP). The specific GMP and ISO certifications held by S. Thepharm Co., Ltd. are [VERIFY: S. Thepharm GMP/ISO certifications].

The ability to legally source and apply LEXYAL in your practice depends on its specific market registrations:

• European Union & UK: Requires a valid CE Mark. Clinics in these regions must ensure their supplier provides documentation confirming this. For context, detailed regulatory discussions for other products are available, such as the VOM Volume Regulatory Status: Market Access and Certification.
• GCC (Gulf Cooperation Council) & LATAM (Latin America): Market access in these regions typically involves national registrations, often recognizing international standards like the CE Mark or requiring specific country-level health authority approvals. Professionals should verify [VERIFY: LEXYAL registration status in specific GCC/LATAM countries].
• APAC (Asia-Pacific): Beyond KFDA, other APAC countries like Australia (TGA), Japan (PMDA), and Singapore (HSA) have their own regulatory bodies. LEXYAL's specific approvals in these markets are [VERIFY: LEXYAL APAC market registrations].

When sourcing LEXYAL, professionals must be vigilant about the product's origin and distribution chain. Parallel imports, while sometimes legal, can complicate traceability and guarantee of authenticity. Always verify the supplier's credentials and their ability to provide certified products.

Clinics should demand:

• Certificate of Authenticity: Confirming the product is original from S. Thepharm Co., Ltd.
• Lot Numbers & Expiry Dates: Clear and traceable for inventory management and safety recalls.
• Cold Chain Documentation: If applicable for storage requirements.
• Regulatory Documentation: Proof of relevant market approvals (e.g., CE Mark, KFDA). This ensures the product is legitimate for use in your operational jurisdiction. For example, when sourcing other fillers like UNIONFILL, similar documentation should be requested.

For professionals managing clinic economics, wholesale pricing structures are a key factor. Illustrative wholesale pricing for LEXYAL begins at $67.0 per unit. Volume tiers typically offer incremental reductions:

These tiers are designed to support clinics with varying inventory needs. Always engage with suppliers for current pricing and volume incentives.